Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DURHAM, N.C., June 10, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced it has expanded its ADAPT Phase 3 clinical study for AGS-003 to additional top cancer centers in the United States, Canada and will soon be expanding into Europe and Israel.
Help employers find you! Check out all the jobs and post your resume.
DURHAM, N.C., June 10, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced it has expanded its ADAPT Phase 3 clinical study for AGS-003 to additional top cancer centers in the United States, Canada and will soon be expanding into Europe and Israel.
Help employers find you! Check out all the jobs and post your resume.
